Navigation Links
Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
Date:2/24/2011

REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that David Anton, Ph.D. has been promoted to Chief Technology Officer and Senior Vice President, Process Development and Manufacturing, a new position. He will continue to report to Alan Shaw, Ph.D., President and Chief Executive Officer.

Dr. Anton joined Codexis in 2008 after a 25-year career with DuPont. He served as Vice President, Research and Development for Codexis Bioindustrials from 2008-09, and Senior Vice President, Research and Development from 2009-11.  

"Under Dave Anton's leadership, Codexis R&D has grown to an organization that today is developing commercial products and processes in four global markets – biofuels, pharmaceuticals, carbon capture and biobased chemicals," Dr. Shaw said.  "His nearly three decades of experience in technology development and commercialization – including commercial scale-up and manufacturing -  will be important as we continue our transition to a product company."  

Dr. Anton joined DuPont in 1983, and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He was a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee from 2006 to 2008.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the potential expansion of our business.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Robert Lawson, robert.lawson@codexis.com, 650-421-8137


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis to Present at the Jefferies and Pacific Crest Conferences
2. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
3. Codexis to Announce Fourth Quarter 2010 Financial Results on February 3, 2011
4. Codexis to Present at Piper Conference
5. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
6. Codexis Expands Codex® Panel Product Family at CPhI
7. Codexis to Present at the Pacific Crest Technology Leadership Forum
8. Codexis Names Peter Strumph SVP, Commercial Operations
9. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
10. Codexis, Inc. Announces Pricing of Initial Public Offering
11. Codexis Expands Pharmaceutical Manufacturing Partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- Eli Lilly and Company (NYSE: LLY ) today announced ... vitamin regimen patent would not presently be infringed by Actavis ... , Italy and Spain ... dextrose solution.  --> --> ... held that Lilly,s patent would be indirectly infringed by Actavis ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article ... account for a significant portion of hernia repairs throughout the United States. Commenting on ... Hernia Center notes that this trend has not only been expected, but it seems ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... community at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. The ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... cycle of pharmaceutical products, garnering increased attention from all stakeholders in the development ...
(Date:2/12/2016)... ... 12, 2016 , ... As a former television executive, owner Tal Rabinowitz knows ... time to decompress, Rabinowitz found herself drawn to a casual meditation class while working ... her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at ...
Breaking Medicine News(10 mins):